Archives

Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies

B SHANGHAI, April 9, 2026 /PRNewswire/ — Oricell Therapeutics Holdings Limited (“Oricell”), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing…

Read MoreOricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies